Balyasny Asset Management’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
Other funds holding CAPR
Balyasny Asset Management's CAPR Position: Q3 2026 in Review
Balyasny Asset Management increased its Capricor Therapeutics (CAPR) stake by 67% in Q3 2026, buying an estimated $3.61M and bringing the position to 812,718 shares worth $7.7M. The position accounts for 0.01% of the portfolio, ranked #1214.
Balyasny Asset Management first reported a position in CAPR in Q1 2024 and has held it in 6 quarters since. The position peaked at $11.7M in Q2 2026. 158 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.
- Balyasny Asset Management held 812,718 shares of Capricor Therapeutics worth $7.7M as of Q3 2026.
- Balyasny Asset Management bought 325,882 Capricor Therapeutics shares in Q3 2026, an estimated $3.61M.
- Capricor Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q3 2026, its #1214 holding.
- Balyasny Asset Management first reported a position in Capricor Therapeutics in Q1 2024 and has held it in 6 quarters since.
- Balyasny Asset Management's Capricor Therapeutics position peaked at $11.7M in Q2 2026.
- 158 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.
Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.